We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of Patient Features on Opioid Induced End-Tidal CO2 (Capno)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01371903
First Posted: June 13, 2011
Last Update Posted: March 24, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Wayne Triner, Albany Medical College
  Purpose
Emergency department patients receiving opioid pain medicine such as morphine, fentanyl or Dilaudid are eligible. After medication exhaled carbon dioxide is measured. and recorded.

Condition
Opioid Use During Medical Care

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Effect of Patient Features on Opioid Induced End-Tidal CO2

Further study details as provided by Wayne Triner, Albany Medical College:

Primary Outcome Measures:
  • end tidal carbon dioxide [ Time Frame: study start, 30 minutes, 60 minutes, 90 minutes, 120 minutes ]
    measured through small nasal cannula (plastic tube at base of nares)


Enrollment: 278
Study Start Date: August 2010
Study Completion Date: November 2012
Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Detailed Description:
Emergency department patients receiving opioid pain medicine such as morphine, fentanyl, or Dilaudid are eligible. After receiving the pain medication, a small soft plastic tube will be placed between the upper lip and nose. This tube is used to measure the amount of carbon dioxide the patient is breathing out. It can also be used to deliver oxygen if the provider feels the patient needs it. The carbon dioxide breathed out is measured and collected. Other information collected are height, weight, and vital signs. Patient participation time is approximately 2 hours during the emergency department visit.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients receiving opioid such as morphine, fentanyl, or dilaudid during their emergency department visit.
Criteria

Inclusion Criteria:

  • non intubated patients receiving intravenous opioid medications

Exclusion Criteria:

  • mechanically ventilated patients
  • patients with physiologic shock
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01371903


Locations
United States, New York
Albany Medical Center Emergency Department
Albany, New York, United States, 12208
Sponsors and Collaborators
Albany Medical College
  More Information

Responsible Party: Wayne Triner, Professor Emergency Medicine, Albany Medical College
ClinicalTrials.gov Identifier: NCT01371903     History of Changes
Other Study ID Numbers: 2792
First Submitted: June 10, 2011
First Posted: June 13, 2011
Last Update Posted: March 24, 2014
Last Verified: June 2011

Keywords provided by Wayne Triner, Albany Medical College:
morphine
fentanyl
dilaudid
opioid
capnography

Additional relevant MeSH terms:
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents